Regulatory11 May 2026, 08:35 am
Biocon Pharma Gets Health Canada Nod for Micafungin Injection
AI Summary
Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from Health Canada for its micafungin for injection, USP, in 50 mg and 100 mg dosages. The product is approved for treating Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections, esophageal candidiasis, and prophylaxis of Candida infections in hematopoietic stem cell transplantation patients. This approval is expected to strengthen Biocon's portfolio of biosimilars and generics.
Key Highlights
- Biocon Pharma receives Health Canada approval for Micafungin injection.
- The approved product treats various Candida infections in adults and children.
- Micafungin injection is available in 50 mg and 100 mg dosages.
- Approval strengthens Biocon's biosimilars and generics portfolio.